PE20200004A1 - Composicion de vacuna multivalente novedosa - Google Patents

Composicion de vacuna multivalente novedosa

Info

Publication number
PE20200004A1
PE20200004A1 PE2019000409A PE2019000409A PE20200004A1 PE 20200004 A1 PE20200004 A1 PE 20200004A1 PE 2019000409 A PE2019000409 A PE 2019000409A PE 2019000409 A PE2019000409 A PE 2019000409A PE 20200004 A1 PE20200004 A1 PE 20200004A1
Authority
PE
Peru
Prior art keywords
rotavirus
virus
cdc
aluminum
inactivated
Prior art date
Application number
PE2019000409A
Other languages
English (en)
Spanish (es)
Inventor
Sambhaji Shankar Pisal
Jagdish Kamalaji Zade
Rajendra Narayan Sabale
Ravindra Bapurao Kadam
Abhijeet Sanjeev Kamble
Baoming Jiang
Roger Glass
Rajeev Mhalasakant Dhere
Original Assignee
Serum Institute Of India Pvt Ltd
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd, Us Health filed Critical Serum Institute Of India Pvt Ltd
Publication of PE20200004A1 publication Critical patent/PE20200004A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/15Reoviridae, e.g. calf diarrhea virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/099Bordetella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/13Poliovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12311Rotavirus, e.g. rotavirus A
    • C12N2720/12334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PE2019000409A 2016-08-26 2017-08-24 Composicion de vacuna multivalente novedosa PE20200004A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621029037 2016-08-26
PCT/IB2017/055100 WO2018037365A1 (en) 2016-08-26 2017-08-24 Multivalent vaccine composition

Publications (1)

Publication Number Publication Date
PE20200004A1 true PE20200004A1 (es) 2020-01-06

Family

ID=60083359

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000409A PE20200004A1 (es) 2016-08-26 2017-08-24 Composicion de vacuna multivalente novedosa

Country Status (17)

Country Link
US (1) US11235054B2 (https=)
EP (1) EP3503917B1 (https=)
JP (3) JP7384667B2 (https=)
KR (1) KR102607295B1 (https=)
CN (1) CN110691611A (https=)
AU (1) AU2017316768B2 (https=)
CA (1) CA3032901A1 (https=)
CU (1) CU24682B1 (https=)
EA (1) EA201900117A1 (https=)
IL (1) IL264605B2 (https=)
MX (1) MX2019001780A (https=)
MY (1) MY191163A (https=)
PE (1) PE20200004A1 (https=)
PH (1) PH12019500404B1 (https=)
SG (1) SG11201900365WA (https=)
UA (1) UA129115C2 (https=)
WO (1) WO2018037365A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900365WA (en) * 2016-08-26 2019-02-27 Serum Institute Of India Pvt Ltd Multivalent vaccine composition
US11793873B2 (en) 2017-05-10 2023-10-24 University Of Massachusetts Bivalent dengue/hepatitis B vaccines
MX2021004233A (es) * 2018-10-12 2021-08-16 Serum Inst Of India Private Ltd Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma.
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536515A (ja) 2005-04-18 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド ワクチンの調製のためのb型肝炎ウイルス表面抗原の発現
US8945582B2 (en) * 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
CA2763359C (en) 2009-05-12 2021-07-27 Baoming Jiang New human rotavirus strains and vaccines
EP3459562B1 (en) * 2011-01-05 2024-03-20 Bharat Biotech International Limited A combination heptavalent vaccine
WO2012117377A1 (en) * 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
SI3204494T1 (sl) * 2014-10-07 2020-08-31 Serum Institute Of India Private Limited Izboljšane metode za neaktivacijo poliovirusa, adjuvans adsorpcije
SG11201900365WA (en) * 2016-08-26 2019-02-27 Serum Institute Of India Pvt Ltd Multivalent vaccine composition

Also Published As

Publication number Publication date
MX2019001780A (es) 2020-01-13
PH12019500404A1 (en) 2020-01-20
PH12019500404B1 (en) 2024-05-15
AU2017316768B2 (en) 2024-04-11
JP2021181445A (ja) 2021-11-25
EA201900117A1 (ru) 2019-09-30
BR112019003419A2 (pt) 2019-05-21
AU2017316768A1 (en) 2019-04-11
NZ751127A (en) 2025-08-29
EP3503917B1 (en) 2024-07-03
IL264605B2 (en) 2023-04-01
US11235054B2 (en) 2022-02-01
US20190175722A1 (en) 2019-06-13
WO2018037365A1 (en) 2018-03-01
CU20190013A7 (es) 2019-10-04
JP2024009899A (ja) 2024-01-23
KR20190142311A (ko) 2019-12-26
SG11201900365WA (en) 2019-02-27
UA129115C2 (uk) 2025-01-22
IL264605B (en) 2022-12-01
IL264605A (en) 2019-02-28
CU24682B1 (es) 2023-10-06
EP3503917A1 (en) 2019-07-03
MY191163A (en) 2022-06-03
JP2019526635A (ja) 2019-09-19
JP7384667B2 (ja) 2023-11-21
CN110691611A (zh) 2020-01-14
WO2018037365A8 (en) 2018-09-20
CA3032901A1 (en) 2018-03-01
KR102607295B1 (ko) 2023-11-29

Similar Documents

Publication Publication Date Title
UY37811A (es) Una composición inmunogénica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparación de la misma
PE20200004A1 (es) Composicion de vacuna multivalente novedosa
AR092896A1 (es) Composiciones inmunogenicas
CO6430434A2 (es) Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas
BR112018002406A2 (pt) anticorpos que neutralizam potentemente o vírus da hepatite b e usos dos mesmos
BR112013017171A2 (pt) vacina de combinação imunogênica estável, processo de preparação de vacina de combinação estável, método de uso de moléculas antigênicas e método de administração a indivíduos humanos
ES2597832T3 (es) Vacuna acelular contra la tosferina
PE20211648A1 (es) Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma
BRPI0607551A2 (pt) vacinas de combinação de helicobacter e circovìrus porcino e métodos de uso
CO6430435A2 (es) Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas
MX377803B (es) Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas.
AR088907A1 (es) Vacuna
Loucq Vaccines today, vaccines tomorrow: a perspective
AR101256A1 (es) Composición vacunal que comprende ipv y ciclodextrinas
RU2014147491A (ru) Антигены и антигенные композиции
AR118407A1 (es) Composición de vacuna multivalente
Suzan et al. Longevity of vaccination in children with chronic liver disease
NZ751127B2 (en) Multivalent vaccine composition
Al-Jadiry Childhood Immunization
Puig-Barberà et al. Vacunas combinadas (I)
Hull Australian childhood immunisation coverage, assessed as at 31 March 2015
REN et al. Immunogenicity and safety of the acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenza type b conjugate vaccine (DTaP-IPV/Hib combined vaccine): a meta-analysis
AR097217A1 (es) Composiciones inmunógenas de combinación
AR095206A1 (es) Vacuna acelular contra pertussis
Hull Australian childhood immunisation coverage, 1 January to 31 March cohort, assessed as at 30 June 2014